Spinal Stimulation During Exercise in Heart Failure

Heart Failure Clinical Trial

Official title:

Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02659202
• Other study ID #: 14-002521
• Status: Terminated
• Phase: N/A
• Start date: June 2016
• Est. completion date: March 23, 2018

Study information

• Verified date: April 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this proposal is to determine whether epidural spinal cord stimulation can modulate cardiovascular control during exercise in Heart Failure patients.

Description:

Forty Heart Failure (>18 yrs. of age) will be recruited. The study will include a total of 2 visits. All experiments will take place at the Mayo Clinic; at the outpatient radiology for MRI screening, the Charlton Clinical Research Unit (CRU) for surgical suite for spinal cord stimulation placement and the Saint Mary's Hospital Clinical Research Unit for clinical exercise laboratory for the exercise protocol and overnight stay.

Study visit 1 will include eligibility screening, consenting process, completion of a health questionnaire and performance of a peak oxygen consumption (VO2) test. Additionally, subjects will undergo a screening lumbar MRI to ensure that there are no anatomical anomalies in or around the epidural area consistent with standard clinical practice for epidural stimulator lead placement associated with chronic pain syndromes.

Study visit 2 will include an overnight stay in the Saint Mary's Hospital Clinical Research Unit. Patients will check in to the CRU in the morning of day 1, visit 2. Prior to placement of stimulating electrodes an international normalized ratio (INR) will be checked to ensure safe clotting. An anesthesiologist will place the electrodes in the lumbar/thoracic epidural space in a manner that is standard for the clinical placement of temporary electrodes in humans. The participants will then transfer to the clinical exercise laboratory to start the exercise protocol. Participants will rest 15 minutes prior to starting exercise. Exercise will take place on a vertical bike where they will perform a submaximal cycling exercise at 30% of peak work for 29 minutes. Thigh cuffs will be placed on thigh bilaterally and inflated intermittently to pressures of 80m mmHg. After the testing is complete, participants will return to their room in the Clinical Research Unit for the rest of the day and sty over night.

On day two of visit two, participants will repeat the testing from day one with new randomization to determine reliability of testing performed on day one. After the exercise on day two of visit two, the spinal cord stimulator leads and radial arterial catheter will be removed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: March 23, 2018
• Est. primary completion date: March 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria, includes:

• Heart Failure patients with reduced ejection fraction:

• History of ischemic or idiopathic dilated cardiomyopathy (duration > 1yr.) stable for > 3mo and New York Heart Association Class I-III

• Not pacemaker dependent

• Body Mass Index =35

• Ejection Fraction < 40%

• Current nonsmokers with < 15 pack year history

• Able to exercise

Exclusion Criteria includes:

• History of cardiopulmonary disorders and dangerous arrhythmias

• Pregnant women

• Taking prescribed opioid medications or have had a fusion or laminectomy at L3 or above

• Patients with a recent drug-eluding stent

• History of spinal stenosis, lumbar radiculopathy, or peripheral neuropathy

• Must not currently be taking blood thinners or anticoagulant medications.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• Precision Spinal Cord Stimulator System
The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Arterial Pressure	This will allow for continuous real-time intra-arterial measurement of beat-to-beat blood pressure.	2 days

External Links

•   Mayo Clinic Clinical Trials